Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 17, 2022 (5 years ago)

Glycopyrrolate Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: Complaint for pieces of glass discovered in a sealed bottle which came from equipment within the packaging room.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Glycopyrrolate Tablets, USP, 1 mg, 100-count bottle, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, NDC 13107-014-01.

Affected NDC 13107-0014-01

Compare with the code on your package — it is the most precise check available.

Drug: Glycopyrrolate

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Glycopyrrolate
NDC 13107-0014
1 mg/1 Tablet
Oral
Aurolife Pharma LLC Rx
Recalling firm
Aurolife Pharma, LLC
NDC code
13107-014-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0736-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Glycopyrrolate recalls

See all
Class II · Moderate risk

Glycopyrrolate

Lack of Assurance of Sterility: Leaking/damaged syringes.

Ongoing Sterility / contamination Denver Solutions, LLC DBA Leiters Health NDC 71449-104-11 D-0370-2025

Other recalls by Aurolife Pharma, LLC

All 2022 recalls